| Literature DB >> 26157425 |
Mai M Malek1, Fatma A Amer1, Ayman A Allam1, Rehab H El-Sokkary1, Tarek Gheith1, Mohamed A Arafa2.
Abstract
Integrons are genetic units characterized by the ability to capture and incorporate gene cassettes, thus can contribute to the emergence and transfer of antibiotic resistance. The objectives of this study were: (1) to investigate the presence and distribution of class I and class II integrons and the characteristics of the gene cassettes they carry in Enterobacteriaceae isolated from nosocomial infections at Zagzig University Hospital in Egypt, (2) to determine their impact on resistance, and (3) to identify risk factors for the existence of integrons. Relevant samples and full clinical history were collected from 118 inpatients. Samples were processed; isolated microbes were identified and tested for antibiotic susceptibilities. Integrons were detected by polymerase chain reaction (PCR) and were characterized into class I or II by restriction fragment length polymorphism (RFLP). Integron-positive isolates were subjected to another PCR to detect gene cassette, followed by gene cassette sequencing. Risk factors were analyzed by logistic regression analysis. Seventy-six Enterobacteriaceae isolates were recognized, 41 of them (53.9%) were integron-positive; 39 strains carried class I and 2 strains carried class II integrons. Integrons had gene cassettes encoding different combinations and types of resistance determinants. Interestingly, blaOXA129 gene was found and ereA gene was carried on class I integrons. The same determinants were carried within isolates of the same species as well as isolates of different species. The presence of integrons was significantly associated with multidrug resistance (MDR). No risk factors were associated for integron carriage. We conclude that integrons carrying gene cassettes encoding antibiotic resistance are significantly present among Enterobacteriaceae causing nosocomial infection in our hospital. Risk factors for acquisition remain to be identified.Entities:
Keywords: Enterobacteriaceae; MDR; integron; risk factors; sequencing
Year: 2015 PMID: 26157425 PMCID: PMC4477160 DOI: 10.3389/fmicb.2015.00601
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Origin and type of the strains included in the study.
| ICU | 8 | 21 | 11 | 12 | 52 | 42 | (80.8%) |
| Orthopedic unit | – | 9 | 4 | – | 13 | 8 | (61.5%) |
| Neonatology unit | – | – | – | 10 | 10 | 6 | (60%) |
| Chest unit | 5 | 4 | 4 | 2 | 15 | 8 | (53.3%) |
| Surgery unit | – | 17 | 11 | – | 28 | 12 | (42.9%) |
| Total | 13 | 51 | 30 | 24 | 118 | 76 | (64.4%) |
Figure 1Distribution of different species of Enterobacteriacae.
Detection of class I and class II integrons by PCR–RFLP.
| 40 | 17 (42.5) | 1 (2.5) | 18 (45) | |
| 18 | 14 (77.8) | 1 (5.5) | 15 (83.3) | |
| 3 | 1 (33.3) | 2 (66.6) | ||
| 2 | 1 (50) | 1 (50) | ||
| 2 | 1 (50) | 1 (50) | ||
| 1 | 0 (0.0) | 0 (0.0) | ||
| 6 | 3 (50) | 3 (50) | ||
| 3 | 1 (33.3) | 1 (33.3) | ||
| 1 | 0 (0.0) | 0 (0.0) | ||
| Total | 76 | 39 (51.32) | 2 (2.6) | 41 (53.9) |
Figure 2Ethidium bromide-stained agrose gel showing +ve isolates for integrase gene. Lane M: molecular size marker (100–1000). Lane 1: positive control. Lanes 2–6: 491 (bp PCR product from positive strains). Lane 7: negative control.
Figure 3Ethidium bromide stained agrose gel showing +ve class I and class II integron with RFLP by restriction enzyme digestion. Lane M: molecular size marker (100–1000). Lanes 1, 2: 2 segments (bands) 334, 157 bp, respectively. Lanes 3–6: 491 (bp PCR product class 1 positive strain). Lane 7: negative control.
Occurrence and characterization of gene cassettes carried by of class I integrons.
| 2 | ||
| 2 | ||
| 2 | ||
| 1 | ||
| 1 | ||
| 3 | ||
| 1 | ||
| 3 | ||
| 2 | ||
| 2 | ||
| 1 | ||
| 2 | ||
| 3 | ||
| 2 | ||
| 2 | ||
| Not determined | 2 | |
| 2 | ||
| Not determined | 1 | |
| 1 | ||
| 1 | ||
| 1 | ||
| 1 | ||
| 1 |
dfr, Dihydrofolate reductases; arr, rifampicin resistance; cmi, chloramphenicol resistance protein; OXA, oxasillinase; aac, aminoglycoside acetyltransferases; aph, 3-O-phosphotransferase; aad, aminoglycoside adenylyltransferases B; qac, quaternary ammonium compound; TEM, beta lactamase gene; bla P, beta lactamase gene.
Association between antibiotic resistance and integron positivity.
| Amikacin | 22 | 31.5 | 18 | 81.8 | 0.0164 |
| Amoxicillin+clavulanic | 76 | 100 | 40 | 52.6 | 0.779 |
| Ampicillin+sulbactam | 66 | 86.8 | 35 | 35.03 | 0.7634 |
| Azithromycin | 64 | 84.2 | 35 | 54.7 | 0.646 |
| Cefepime | 47 | 61.8 | 33 | 70.3 | 0.0302 |
| Cefixime | 34 | 44.7 | 18 | 52.9 | 0.731 |
| Cefotaxime | 45 | 59.2 | 25 | 55.6 | 0.586 |
| Cefoxitin | 25 | 32.8 | 11 | 44.0 | 0.806 |
| Cefperazone | 51 | 67.1 | 36 | 70.6 | 0.169 |
| Ceftazidime | 44 | 57.8 | 29 | 65.9 | 0.0163 |
| Ceftriaxone | 53 | 69.7 | 39 | 73.6 | 0.006 |
| Chloramphenicol | 20 | 26.3 | 16 | 80.0 | 0.0293 |
| Gentamycin | 29 | 28.9 | 23 | 79.3 | 0.0108 |
| Levofloxacin | 11 | 14.4 | 10 | 90.9 | 0.0273 |
| Trimethoprim-sulphamethexazole | 48 | 63.1 | 39 | 81.3 | 0.001 |
Level of significance: P < 0.05 indicates significant results.
Resistance profile of 51 MDR.
| Aminoglycosides, extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, chloramphenicol, cephamycins | 5 | 1 | |
| Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, cephamycins | 8 | 4 | |
| Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+b-lactamase, quinolones, aminoglycosides | 3 | 0 | |
| Penicillins+b-lactamase inhibitors, chloramphenicol, cephamycins | 1 | 1 | |
| Extended-spectrum cephalosporins, penicillins+β-lactamase inhibitors, chloramphenicol, cephamycins | 0 | 4 | |
| Penicillins+β-lactamase inhibitors, chloramphenicol, cephamycins | 3 | 2 | |
| Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, quinolones | 2 | 1 | |
| Aminoglycosides, extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, Chloramphenicol, Cephamycins | 2 | 1 | |
| Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors | 1 | 2 | |
| Folate pathway inhibitors, penicillins+β-lactamase inhibitors, cephamycins | 1 | 0 | |
| Aminoglycosides, extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, chloramphenicol, cephamycins | 1 | 0 | |
| Aminoglycosides; folate pathway inhibitors, penicillins+β-lactamase inhibitors, chloramphenicol, cephamycins, quinolones | 1 | 1 | |
| Aminoglycosides, extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, chloramphenicol, cephamycins | 1 | 0 | |
| Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, cephamycins, quinolones | 1 | 0 | |
| Aminoglycosides, Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, cephamycins | 1 | 0 | |
| Folate pathway inhibitors, penicillins+β-lactamase inhibitors, cephamycins, quinolones, chloramphenicol | 1 | 1 | |
| Aminoglycosides, Extended-spectrum cephalosporins; folate pathway inhibitors, penicillins+β-lactamase inhibitors, chloramphenicol cephamycins | 1 | 0 | |
Categories used in this table to identify MDR are those recommended by the European Society of clinical Microbiology and Infectious Diseases (Magiorakos et al., .
Relation between integron presence and MDR among .
| Integron +ve ( | 33 (64.7) | 9 (36) | 4.491 | 0.017 |
| Integron −ve ( | 18 (35.3) | 16 (64) | ||
| Total | 51 (100) | 25 (100) | ||
χ2, Chi square test;
level of significans (p < 0.05).
Association between risk factors and presence of integron (Chi square test).
| Trauma | 55 | 38 | 69.1 | 17 | 30.9 | 0.029 |
| Hospitalization more than 7 days | 20 | 17 | 85 | 3 | 15 | 0.011 |
| ICU admission | 34 | 29 | 85.3 | 5 | 14.7 | 0.002 |
| Ventilator | 10 | 8 | 80 | 2 | 20 | 0.235 |
| Urinary catheter | 28 | 7 | 25 | 21 | 75 | 0.357 |
| Central venous catheter | 5 | 4 | 80 | 1 | 20 | 0.586 |
Chi square test.
Logistic regression analysis for significant predictors of the presence of integron among the studied groups.
| Trauma | 22.02 | 7.26 | 0.02 | 0.98 | 3.64 (0.07–5.15) |
| Hospitalization more than 7 days | 20.17 | 8.27 | 0.04 | 0.96 | 5.73 (1.02–7.45) |
| ICU admission | 42.03 | 1.10 | 0.03 | 0.90 | 0.01 (0.00–0.06) |
B, Regression coefficients; S.E., standard error around the coefficient for the constant; Wald, Wald chi-square test statistic; Sig. P-value for Wald test; OR, odds ratio.